#1 Clinical Trials Search in Europe

Insulin Human (Rdna)

This article delves into the use of Insulin Human (rDNA) in clinical trials, focusing on its role in managing diabetes and related conditions. Insulin Human (rDNA) is a synthetic form of insulin that closely mimics the insulin naturally produced by the human body. These trials aim to improve our understanding of how this insulin type can be used more effectively in various patient populations, including those with kidney disease and different gastric emptying rates.

Table of Contents

What is INSULIN HUMAN (RDNA)?

INSULIN HUMAN (RDNA), also known as recombinant human insulin, is a synthetic form of insulin produced using genetic engineering techniques[1]. This medication is designed to mimic the insulin naturally produced by the human body. It’s important to note that INSULIN HUMAN (RDNA) is also referred to by several other names, including:

  • Insulin, human biosynthetic
  • Insulin human, rDNA
  • Insulin human biosynthetic
  • Insulin human recombinant
  • Insulin human (genetical recombination)

These various names all refer to the same medication, which is a laboratory-created version of human insulin[1].

Medical Conditions Treated

INSULIN HUMAN (RDNA) is primarily used to treat diabetes mellitus, a condition characterized by high blood sugar levels. It’s most commonly used in the treatment of type 1 diabetes, but it can also be used in some cases of type 2 diabetes[2]. In type 1 diabetes, the body doesn’t produce insulin, while in type 2 diabetes, the body doesn’t use insulin effectively.

Additionally, this medication may be used in the management of insulin resistance, a condition where the body’s cells don’t respond well to insulin, leading to high blood sugar levels[1].

How It Works

INSULIN HUMAN (RDNA) works by mimicking the action of natural insulin in the body. Insulin is a hormone that helps regulate blood sugar levels by:

  • Allowing cells in the body to absorb glucose (sugar) from the bloodstream
  • Promoting the storage of excess glucose in the liver and muscles as glycogen
  • Inhibiting the production of glucose by the liver

By performing these functions, INSULIN HUMAN (RDNA) helps to lower blood sugar levels and maintain them within a healthy range[2].

Administration

INSULIN HUMAN (RDNA) is typically administered via subcutaneous injection or intravenous infusion[1][3]. The specific dosage and administration schedule will depend on individual patient needs and should be determined by a healthcare professional. It’s important to follow the prescribed regimen carefully to maintain optimal blood sugar control.

Potential Side Effects

While INSULIN HUMAN (RDNA) is generally well-tolerated, it can cause side effects in some patients. The most common and serious side effect is hypoglycemia (low blood sugar). Symptoms of hypoglycemia may include:

  • Shakiness
  • Dizziness
  • Sweating
  • Confusion
  • Rapid heartbeat

Other potential side effects may include injection site reactions, allergic reactions, and weight gain. It’s important to discuss any side effects with your healthcare provider[2].

Ongoing Research

Research is ongoing to further understand the effects and optimal use of INSULIN HUMAN (RDNA). Current studies are exploring its use in various contexts:

  • A study is investigating the effect of INSULIN HUMAN (RDNA) on insulin resistance in kidney transplant recipients and patients with chronic kidney disease[1].
  • Another study is examining the safety and local tolerability of multiple doses of a new insulin formulation in subjects with elevated triglyceride plasma concentrations[2].
  • Researchers are also comparing the effectiveness of different fast-acting mealtime insulin preparations, including INSULIN HUMAN (RDNA), in individuals with type 1 diabetes who have varying rates of gastric emptying[3].

Important Considerations

When using INSULIN HUMAN (RDNA), it’s crucial to:

  • Regularly monitor your blood sugar levels as directed by your healthcare provider.
  • Be aware of the signs and symptoms of hypoglycemia and how to treat it.
  • Maintain a consistent diet and exercise routine, as changes can affect your insulin needs.
  • Inform all healthcare providers about your insulin use, especially before any surgical procedures.
  • Store the insulin properly according to the manufacturer’s instructions.

Always consult with your healthcare provider for personalized advice and guidance on using INSULIN HUMAN (RDNA)[2][3].

Aspect Details
Primary Focus Use of Insulin Human (rDNA) in managing diabetes and related conditions
Patient Groups Type 1 diabetes, kidney disease patients, individuals with high triglycerides
Key Objectives Assess insulin sensitivity, optimize blood glucose control, evaluate safety and tolerability
Measurement Methods Blood glucose levels, insulin sensitivity tests, triglyceride levels, oxidative stress markers
Potential Benefits Improved glucose control, better management of insulin resistance, reduced complications
Unique Aspects Consideration of gastric emptying rates, combination with other medications (e.g., statins)

FAQ

  • What is Insulin Human (rDNA)? Insulin Human (rDNA) is a synthetic form of insulin that is genetically engineered to be identical to human insulin. It's used to manage blood sugar levels in people with diabetes.
  • How is Insulin Human (rDNA) being studied in clinical trials? Clinical trials are exploring its use in various patient groups, including those with kidney disease, type 1 diabetes with different gastric emptying rates, and in combination with other medications like statins for managing triglyceride levels.
  • What are the potential benefits of using Insulin Human (rDNA)? Potential benefits include improved blood sugar control, better management of insulin resistance, and possibly reduced complications in patients with conditions like kidney disease or high triglyceride levels.
  • Are there any specific patient groups being targeted in these trials? Yes, the trials are focusing on patients with type 1 diabetes, those with kidney disease (including transplant recipients), and individuals with elevated triglyceride levels.
  • How is the effectiveness of Insulin Human (rDNA) measured in these trials? Effectiveness is measured through various methods, including blood glucose levels, insulin sensitivity, triglyceride levels, and in some cases, markers of oxidative stress.

Ongoing Clinical Trials on Insulin Human (Rdna)

  • Study on the Safety of A24110He for Patients with Type 2 Diabetes and High Triglycerides

    Not recruiting

    2 1 1
    Investigated drugs:
    Sweden

  • Study on Insulin Lispro and Insulin Human for Managing Blood Sugar After Meals in Type 1 Diabetes Patients with Different Gastric Emptying Rates

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Pravastatin’s Effect on Insulin Resistance in Kidney Transplant and Chronic Kidney Disease Patients

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

Glossary

  • Insulin Human (rDNA): A synthetic form of insulin produced through recombinant DNA technology, designed to be identical to human insulin.
  • Type 1 Diabetes: A chronic condition where the pancreas produces little or no insulin, requiring lifelong insulin therapy.
  • Insulin Resistance: A condition where cells in the body don't respond well to insulin and can't easily take up glucose from the blood.
  • Hypertriglyceridemia: A condition characterized by high levels of triglycerides (a type of fat) in the blood.
  • Gastric Emptying: The process by which food leaves the stomach and enters the small intestine.
  • HbA1c: A blood test that measures average blood sugar levels over the past 2-3 months.
  • Euglycemic Glucose Clamp: A method used to measure insulin sensitivity by maintaining a constant blood glucose level while infusing insulin.
  • Reactive Oxygen Species (ROS): Unstable molecules containing oxygen that can damage cells and contribute to oxidative stress.
  • eGFR: Estimated Glomerular Filtration Rate, a measure of kidney function.

References

  1. http://clinicaltrials.eu/trial/study-on-pravastatins-effect-on-insulin-resistance-in-kidney-transplant-and-chronic-kidney-disease-patients/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-of-a24110he-for-patients-with-type-2-diabetes-and-high-triglycerides/
  3. http://clinicaltrials.eu/trial/study-on-insulin-lispro-and-insulin-human-for-managing-blood-sugar-after-meals-in-type-1-diabetes-patients-with-different-gastric-emptying-rates/